The size of the Anatomic Pathology Market in the Asia Pacific is estimated to worth USD 2.92 billion in 2020. It is expected to be growing at a CAGR of 7.92% to reach USD 4.27 billion by 2025.
The market in this region is displaying obvious potential in the said determining period. Anatomy Pathology is the branch of medicine that deals with the diagnosis of diseases based on the various levels of examinations of organs and tissues.
Anatomy Pathology features disease diagnosis based on the macroscopic, microscopic, biochemical, immunologic, and molecular examination of organs and tissues. The data generated by Anatomy Pathology is further analyzed and is used by doctors for better health management. Anatomy Pathology is one of the branches of the pathology stream, other being the Clinical Pathology.
With the enormous number of ongoing developments and innovations in healthcare, rising spending capabilities, and increasing awareness of the people in this region, there has also been a rise in the market. People have also become prone to more and more harmful diseases as time has changed because of the increasing adaptability of micro-organisms against various medications. This market is facing challenges mainly competing with the Physician Groups, like specialty physicians merging or adding ancillary services and large commercial labs. There is a constant significant reimbursement pressure. Awareness is increasing in this region about diseases at a rapid rate; still, overall knowledge of the people is very less. These factors may act as growth hurdles for the Anatomy Pathology Market in this region.
This report segmented and sub-segmented into the following categories:
The Asia Pacific is one of the most lucrative markets for the Anatomy Pathology market's growth and is projected to grow the highest during the forecast period. Factors such as growing demographics and emerging economies in countries such as India and China are anticipated to lead the growth of the market in this region.
Countries like China, India, and Japan are playing a leading role in the Asia Pacific anatomic pathology market and is expected to witness highest growth rate in the global market due to the increasing knowledge related to the significance of anatomic pathology investigation amidst health practitioners which propel the market growth in this region. Moreover, the anatomic pathology market is projected to have an augmented requirement for advanced technological imaging modalities, increase in patient care initiatives, and increase the number of pathology laboratories that fuel market growth throughout the review period.
The Japanese anatomic pathology market is expected to hike at a healthy growth rate due to rising academic and government investments in research for diagnostics and increasing recognition regarding the usage of the anatomic pathology test regarding the physicians, which is likely to boost the growth in this region. Escalating usage of advanced pathology equipment like gross imaging, digital microscopes, and staining systems are decided to develop anatomic pathology equipment market growth during the review period.
India is likely to have projectable growth during the period as of increasing awareness for medical testing services, assistance from the government in advancing the healthcare sector, and the invention of new and developed testing procedures by key players of this region. Rising usage of biomarkers during the disease diagnosis is expected to drive the anatomic pathology market throughout the analysis period.
The Asia Pacific Anatomic Pathology Market is highly monopolized in this region. Some of the major companies dominating the market in this region are Sakura Fine technical Co., Ltd. (Japan), Metropolis (India), and IBISWorld’s Pathology Services (Australia).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Instruments
5.1.3 Accessories
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 End-User
5.2.1 Introduction
5.2.2 Diagnostics Lab
5.2.3 Hospitals
5.2.4 Physicians' Office Lab
5.2.5 Y-o-Y Growth Analysis, By End-User
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By End-User
5.3 Application
5.3.1 Introduction
5.3.2 Lymphoma
5.3.3 Breast
5.3.4 Lung
5.3.5 Cervical
5.3.6 Colorectal
5.3.7 Prostate
5.3.8 Y-o-Y Growth Analysis, By Application
5.3.9 Market Attractiveness Analysis, By Application
5.3.10 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type End-User
6.1.3.4 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type End-User
6.1.4.4 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type End-User
6.1.5.4 By Application
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 F. Hoffmann-La Roche AG
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 NeoGenomics Laboratories Inc.
8.3 Laboratory Corporation of America Holdings
8.4 Thermo Fisher Scientific
8.5 Quest Diagnostics Incorporated
8.6 Agilent Technologies
8.7 Danaher Corporation
8.8 Sakura Finetechnical Co. Ltd.
8.9 Metropolis
8.10 IBISWorld’s Pathology Services
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
